Sanofi discussed $275 per Actelion share for deal

News Hour:

French drugmaker Sanofi is in advanced talks to buy Actelion Ltd and is discussing a price of about $275 per share for the Swiss drugmaker, Bloomberg reported on Thursday.

The potential deal, which could come as soon as next week, would value Actelion at about $29.6 billion, Bloomberg reported, citing people with knowledge of the matter, reports Reuters.

Actelion is in talks with Sanofi about a deal, Reuters reported on Wednesday, after U.S. healthcare group Johnson & Johnson abandoned efforts to buy the company. Sanofi and Actelion could not immediately be reached for comment.

Avatar

This article has been posted by a News Hour Correspondent. For queries, please contact through [email protected]
No Comments

Translate this News

Join the Facebook Group

Click here to join the Facebook group of News Hour

Popular Posts

Sacred Games exposes Rajshri Deshpande nude [video]
Paperfly launches delivery services covering 64 districts in Bangladesh
The miracle of Hyperbaric Oxygen Therapy (HBOT) and its potential in Bangladesh
Google to move into banking by offering current accounts
One child dies of pneumonia every 39 seconds
Man damages his own brain to forget the Infinity War spoilers he saw before

Advertisement

News of the Month

Scroll Up
%d bloggers like this: